Coronavirus vaccine breakthrough as scientists confirm plans for mass-production

The UK coronavirus vaccine has taken a major step forwards after scientists revealed plans for mass-production if trials are successful.

The University of Oxford has partnered with pharmaceutical giant AstraZeneca for the development, manufacture and large-scale distribution of the Covid-19 vaccine candidate that is currently being trialled in the UK.

The agreement was announced on Thursday, with the details set to be finalised in the coming weeks.

The move will allow for rapid vaccination around the world if the candidate proves to be effective, the university said.

Human trials of the vaccine developed by the University’s Jenner Institute began last week, with hundreds of people volunteering to be part of the study which received £20 million in Government funding.

Professor Sir John Bell, Regius Professor of Medicine at Oxford University described the partnership with AstraZeneca as a “major force in the struggle against pandemics” for the foreseeable future.

Speaking on BBC Radio 4’s Today programme, Sir John said he hoped that some results from a human trial of the vaccine would be available by the middle of June.

He told Today that the challenge now is to be able to manufacture at scale once it is approved by the regulators.

Sir John added: “We also want to make sure that the rest of the world will be ready to make this vaccine at scale so that it gets to populations in developing countries, for example, where the need is very great.

“We really need a partner to do that and that partner has a big job in the UK because our manufacturing capacity in the UK for vaccines isn’t where it needs to be, and so we are going to work together with AstraZeneca to improve that considerably.”

It is the first such partnership to be formed since the Government launched the Vaccines Taskforce two weeks ago to help find a new coronavirus vaccine.

Both partners have agreed to operate on a not-for-profit basis for the duration of the pandemic, the university said, with only the costs of production and distribution being covered.